Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Let's call a spade, a spade

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Apr 30, 2024 10:33am

87 Views

Post# 36014710

RE:RE:RE:Let's call a spade, a spade

Also the CFO said we should be alright to repay Marathon with the cash on hand and cashflow forcast. They have a 36 payment scheduale starting in august he said. Also discussing how to repay Marathon faster possibility. Last time I heard something like that it was september 2023. Unless they deliver a pertnership with some serious upfront I think we are looking at the front bumber of a bus once again post AGM.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023